Literature DB >> 2839158

Differential effects of suramin on the coupling of receptors to individual species of pertussis-toxin-sensitive guanine-nucleotide-binding proteins.

S J Butler1, E C Kelly, F R McKenzie, S B Guild, M J Wakelam, G Milligan.   

Abstract

The anti-helminthic drug suramin inhibited the basal high-affinity GTPase activity of both C6 BU1 glioma and NG 108-15 neuroblastoma x glioma hybrid-cell membranes with an IC50 (concentration causing half-maximal inhibition) value close to 30 micrograms/ml. This effect was shown to occur via a non-competitive mechanism in which the binding affinity of the G-proteins for GTP was not altered, but the maximal velocity of the subsequent hydrolysis was reduced. In NG 108-15 membranes, both opioid peptides and foetal-calf serum stimulated high-affinity GTPase activity in a pertussis-toxin-sensitive manner. These effects have previously been shown to be mediated by different G-proteins [McKenzie, Kelly, Unson, Spiegel & Milligan (1988) Biochem. J. 249, 653-659]. Suramin completely prevented the opioid-peptide-stimulated increase in GTP hydrolysis, but did not prevent the opioid peptide from binding to its receptor. Suramin, however, did not block the foetal-calf-serum-stimulated GTPase response. This selective action of suramin provides further evidence for distinct roles for two separate pertussis-toxin-sensitive G-proteins in signal transduction in NG 108-15 membranes and provides the first evidence for a selective effect of a drug on the functions of different G-proteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839158      PMCID: PMC1148984          DOI: 10.1042/bj2510201

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Morphine receptors as regulators of adenylate cyclase activity.

Authors:  S K Sharma; M Nirenberg; W A Klee
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain.

Authors:  P Gierschik; G Milligan; M Pines; P Goldsmith; J Codina; W Klee; A Spiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

4.  The GTP-binding regulatory proteins of neuroblastoma x glioma, NG108-15, and glioma, C6, cells. Immunochemical evidence of a pertussis toxin substrate that is neither Ni nor No.

Authors:  G Milligan; P Gierschik; A M Spiegel; W A Klee
Journal:  FEBS Lett       Date:  1986-01-20       Impact factor: 4.124

5.  Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies.

Authors:  L T Williams; P M Tremble; M F Lavin; M E Sunday
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

6.  Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein.

Authors:  T Katada; M Ui
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

7.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

8.  Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin.

Authors:  C Betsholtz; A Johnsson; C H Heldin; B Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

9.  Opiates inhibit adenylate cyclase by stimulating GTP hydrolysis.

Authors:  G Koski; W A Klee
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  The GTP-binding protein, Go, regulates neuronal calcium channels.

Authors:  J Hescheler; W Rosenthal; W Trautwein; G Schultz
Journal:  Nature       Date:  1987 Jan 29-Feb 4       Impact factor: 49.962

View more
  18 in total

1.  Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 5'-diphosphate.

Authors:  S M Hourani; D A Hall; C J Nieman
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

2.  Suramin affects coupling of rhodopsin to transducin.

Authors:  Nicole Lehmann; Gopala Krishna Aradhyam; Karim Fahmy
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

3.  Heparin and other polyanions uncouple alpha 1-adrenoceptors from G-proteins.

Authors:  L L Dasso; C W Taylor
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

4.  Differential regulation of amounts of the guanine-nucleotide-binding proteins Gi and Go in neuroblastoma x glioma hybrid cells in response to dibutyryl cyclic AMP.

Authors:  I Mullaney; A I Magee; C G Unson; G Milligan
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

Review 5.  Suramin: an anticancer drug with unique biological effects.

Authors:  A K Larsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Gsalpha-selective G protein antagonists.

Authors:  M Hohenegger; M Waldhoer; W Beindl; B Böing; A Kreimeyer; P Nickel; C Nanoff; M Freissmuth
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

7.  The P(2)-purinoceptor antagonist suramin is a competitive antagonist at vasoactive intestinal peptide receptors in the rat gastric fundus.

Authors:  K M Jenkinson; J J Reid
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.

Authors:  D J Trezise; I Kennedy; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli.

Authors:  C H Hoyle; G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

10.  Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.

Authors:  John J Laterra; Stuart A Grossman; Kathryn A Carson; Glenn J Lesser; Fred H Hochberg; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.